Expertise in
6
conditions

Lara H. Bohmer

Haag, LI, NL 
Expertise in
6
conditions
Haag, LI, NL 

Overview

Lara Bohmer practices practicing medicine in Haag, Netherlands.

Ms. Bohmer is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Diffuse Large B-Cell Lymphoma (DLBCL), Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, and B-Cell Lymphoma.

She is actively involved in clinical research, co-authoring 28 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Haag, LI 2545AA, Netherlands
Other Locations
The Hague, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2026
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: March 05, 2025
Intervention Type: Drug
Study Drugs: R-CHOP, R-CHOP/R-HAD, Rituximab, Lenalidomide
Study Phase: Phase 3
View 1 Less Clinical Trial

28 Total Publications

Knowledge gaps among adult Hodgkin lymphoma survivors: implications for risk‑based care.
Knowledge gaps among adult Hodgkin lymphoma survivors: implications for risk‑based care.
Journal: Journal of cancer survivorship : research and practice
Published: April 20, 2026

Frequently Asked Questions about Lara H. Bohmer

Is Lara H. Bohmer a top-rated expert for Diffuse Large B-Cell Lymphoma (DLBCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Lara H. Bohmer is classified as an Distinguished expert for Diffuse Large B-Cell Lymphoma (DLBCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Lara H. Bohmer participate in research or clinical trials?

Yes. Lara H. Bohmer has published 28 articles and abstracts on conditions like Diffuse Large B-Cell Lymphoma (DLBCL). You can view a list of Lara H. Bohmer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Bohmer's expertise for a condition
ConditionClose
    View All 10 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile